Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Passage Bio Inc (NQ: PASG )

1.280 -0.070 (-5.19%)
Streaming Delayed Price Updated: 11:15 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Passage Bio Inc

< Previous 1 2 Next >
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
From Passage Bio
Via GlobeNewswire
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Passage Bio
Via GlobeNewswire
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Cowen 43rd Annual Health Care Conference
From Passage Bio
Via GlobeNewswire
Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
From Passage Bio
Via GlobeNewswire
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
From Passage Bio
Via GlobeNewswire
Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day
From Passage Bio
Via GlobeNewswire
Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Passage Bio
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.